Metraipolis › archive › dc_db583d0f66ec

Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41884321
DOI
10.7759/cureus.105738
License (as archived)
solo-consultazione
Archived
2026-11-04T02:44:08.728Z
SHA-256 of the archived text
8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa
Stable URL of this page
https://metraipolis.com/documento/dc_db583d0f66ec

How to cite

Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321 — Europe PMC (en), https://europepmc.org/article/MED/41884321 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db583d0f66ec (Metraipolis archive dc_db583d0f66ec, sha256 8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa)
BibTeX
@misc{dcdb583d0f66ec,
  title = {Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases:… — Europe PMC PMID:41884321},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41884321},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db583d0f66ec; sha256 8446173f6f92335a51e96b3757d023d9dcb940fa625049f72fd2614eb92a64aa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41884321. Agents can read the archived copy with the MCP tool read_document.